BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Toronto S.E. Other stock markets 16:00:00 2023-06-29 EDT			5-day change	1st Jan Change
19.48 ^CAD	-0.10%		-.--%	-

07-23	BluEnergies Completes C$20.7 Million Private Placement; Haywood Advisory Deal Extended	MT
07-21	BluEnergies Upsizes Private Placement to C$20.7 Million on Strong Demand	MT

Market Cap	1.86B 1.62B 1.51B 1.39B 2.62B 178B 2.66B 17.79B 6.98B 88.63B 7B 6.85B 297B	P/E 2021	-8.95x	P/E 2022	-12.4x
Enterprise Value	1.53B 1.33B 1.24B 1.14B 2.15B 146B 2.18B 14.58B 5.72B 72.67B 5.74B 5.62B 244B	EV / Sales 2021	36,416x	EV / Sales 2022	43,771x
Free-Float	81.52%	Yield 2021 *	-	Yield 2022	-

07-23	BluEnergies Completes C$20.7 Million Private Placement; Haywood Advisory Deal Extended	MT
07-21	BluEnergies Upsizes Private Placement to C$20.7 Million on Strong Demand	MT
07-09	BluEnergies to Raise C$10.13 Million Via Non-Brokered Private Placement of Units	MT
07-06	BluEnergies Says Liberia's Harper Basin Exploration Progressing as Planned	MT
04-27	BluEnergies Announces DTC Eligibility	MT
03-30	BluEnergies Says Its Shares Have Begun Trading on OTCQX Best Market	MT
25-05-08	BluEnergies Names Craig Steinke as Chief Executive	MT
23-06-29	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index	CI
23-06-29	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index	CI
23-06-29	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Composite Index	CI
23-06-29	BELLUS Health Inc.(TSX:BLU) dropped from S&P Global BMI Index	CI
23-06-28	GSK completes acquisition of chronic cough-focused Bellus Health	AN
23-06-28	GSK Completes $2 Billion Acquisition of BELLUS Health	MT

23-04-19	RBC Downgrades BELLUS Health to Sector Perform From Outperform, Cuts Price Target to $14.75 From $21 Amid GSK Deal; Speculative Risk Kept	MT
23-04-18	Jefferies Downgrades BELLUS Health to Hold From Buy, Cuts Price Target to $14.75 From $21	MT
23-04-18	BTIG Downgrades BELLUS Health to Neutral From Buy	MT
23-04-18	LifeSci Capital Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $24	MT
23-04-18	TD Cowen Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $15	MT

BELLUS Health Stock

Stocks

BLU

CA07987C2040

Biotechnology & Medical Research

Valuation: BELLUS Health

Latest news : BELLUS Health

Analysts' recommendations: BELLUS Health

Press Releases: BELLUS Health

News in other languages: BELLUS Health

Quotes and Performance

Course Extremes

Managers and Directors: BELLUS Health

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

24-09-30	Bloom Burton & Co. - Roberto Bellini Receives the 2024 Bloom Burton Award	AQ
24-08-02	Chronic Refractory Cough Pipeline 2024 \| GSK, Trevi Therapeutics	AQ
23-06-28	BELLUS Health : MATERIAL CHANGE REPORT - Form 6-K	PU
23-06-28	GSK completes acquisition of BELLUS Health \| GSK	AQ
23-06-28	Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health	AQ

23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door
23-12-11	Farmaceutica e salute: continua il consolidamento
23-12-11	Farmacia y salud: La consolidación continúa
23-06-28	GSK : l'acquisition de Bellus Health est finalisée

Manager	Title	Age	Since
Jeremy Martin PSD	President	-	2023-05-31
Ramzi Benamar DFI	Director of Finance/CFO	53	2020-12-06
Denis Garceau CTO	Chief Tech/Sci/R&D Officer	69	2009-12-31

Director	Title	Age	Since
Francesco Bellini CHM	Chairman	79	2001-12-31
Pierre Larochelle BRD	Director/Board Member	54	2009-05-31
Joseph Rus BRD	Director/Board Member	80	2009-05-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/29/23	GSK PLC	Other	Company	0	0%
6/22/23	Pierre Larochelle	Option	Director	27,777	0.0219%
6/22/23	Tony Matzouranis	Option	Executive/Senior Manager	75,000	0.0593%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BELLUS HEALTH	-0.10%	-.--%	-.--%	-.--%	1.87B
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+33.41%	+79.20%	55.23B
ARGENX SE	-0.21%	-7.38%	+25.34%	+63.02%	53.75B
BIONTECH SE	-2.44%	+1.40%	-15.74%	-16.80%	23.48B
INSMED INCORPORATED	-2.85%	-7.78%	-8.09%	+346.36%	22B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-0.92%	+20.31%	-12.15%	19.78B
GENMAB A/S	+0.79%	-1.06%	+29.29%	-33.32%	17.44B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-5.88%	+16.30%	+540.37%	14.66B
EXELIXIS, INC.	-5.25%	-4.23%	+46.41%	+169.05%	14.07B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+163.08%	+280.43%	13.02B
Average	-0.12%	-3.06%	+31.03%	+141.61%	23.53B
Weighted average by Cap.	+0.17%	-2.73%	+27.99%	+119.49%

	2021	2022
Net sales	16K 13.91K 12.95K 11.89K 22.45K 1.53M 22.79K 153K 59.89K 760K 60.09K 58.77K 2.55M	16K 13.91K 12.95K 11.89K 22.45K 1.53M 22.79K 153K 59.89K 760K 60.09K 58.77K 2.55M
Net income	-71.22M -61.92M -57.63M -52.91M -99.92M -6.8B -101M -679M -267M -3.38B -267M -262M -11.35B	-76.08M -66.14M -61.56M -56.52M -107M -7.26B -108M -726M -285M -3.62B -286M -279M -12.12B
Net Debt	-248M -216M -201M -184M -348M -23.67B -353M -2.36B -928M -11.78B -931M -911M -39.51B	-336M -292M -272M -249M -471M -32.05B -478M -3.2B -1.26B -15.96B -1.26B -1.23B -53.51B

5 years	3.54		19.9
10 years	0.76		19.9